| Symbol | BNTC |
|---|---|
| Name | BENITEC BIOPHARMA INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 3940 TRUST WAY, HAYWARD, California, 94545, United States |
| Telephone | +1 510 780-0819 |
| Fax | — |
| — | |
| Website | https://www.benitec.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | Benitec Biopharma Inc is a biotechnology company developing a proprietary therapeutic technology platform that combines RNA interference with gene therapy for providing sustained, long-lasting silencing of disease-causing genes from a single administration. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The company is developing product candidates in chronic and life-threatening human disease areas including Orphan disease: Oculopharyngeal Muscular Dystrophy (OPMD) and Infectious disease: Hepatitis B Virus (HBV). Additional info from NASDAQ: |
Benitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 at the 2026 American Society of Gene and Cell Therapy Annual Meeting
Read moreBenitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 at the 2026 American Society of Gene and Cell Therapy Annual Meeting
Read moreSeaport Therapeutics Adds Intra-Cellular Therapies Founder and CEO, Dr. Sharon Mates, to its Board of Directors
Read moreBenitec Biopharma to Host Industry Forum Breakfast Event at the2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued Progress for BB-301, the Only Clinical-Stage Therapeutic in Development for Oculopharyngeal Muscular Dystrophy (OPMD)
Read moreBenitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued Progress for BB-301, the Only Clinical-Stage Therapeutic in Development for Oculopharyngeal Muscular Dystrophy (OPMD)
Read moreBenitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 Treatment at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference
Read moreBenitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 Treatment at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference
Read moreBenitec Biopharma Announces Acceptance of Late- Breaking Abstract for the BB-301 Phase 1b/2a Clinical Treatment Study at the Muscular Dystrophy Association Clinical & Scientific Conference
Read moreBenitec Biopharma Releases Second Quarter 2026 Financial Results and Provides Operational Update
Read more(19% Negative) Benitec Biopharma Inc. (BNTC) Reports Q1 2026 Financial Results
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06185673 | A Study to Evaluate the Safety and Clinical Activity of Intramuscular Doses of … | Phase1 | Oculopharyngeal Muscular Dystrophy | Recruiting | 2023-11-28 | 2040-11-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| BB-301: Dose expansion phase 2a | GENETIC | Phase PHASE1 | Oculopharyngeal Muscular Dystrophy | RECRUITING | NCT06185673 |
| BB-301: Dose escalation phase 1b cohort 3 | GENETIC | Phase PHASE1 | Oculopharyngeal Muscular Dystrophy | RECRUITING | NCT06185673 |
| BB-301: Dose escalation phase 1b cohort 2 | GENETIC | Phase PHASE1 | Oculopharyngeal Muscular Dystrophy | RECRUITING | NCT06185673 |
| BB-301: Dose escalation phase 1b cohort 1 | GENETIC | Phase PHASE1 | Oculopharyngeal Muscular Dystrophy | RECRUITING | NCT06185673 |
| BB-401 | DRUG | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma | COMPLETED | NCT03433027 |